Protective effects of quercetin treatment in a pristane-induced mouse model of lupus nephritis

References

• Zharkova O, Celhar T, Cravens PD, et al. Pathways leading to an immunological disease: systemic lupus erythematosus. Rheumatology (Oxford). 2017;56:i55–i66.
   PubMed Web of Science ®Google Scholar
• Borchers AT, Leibushor N, Naguwa SM, et al. Lupus nephritis: a critical review. Autoimmun Rev. 2012;12:174–194.
   PubMed Web of Science ®Google Scholar
• Almaani S, Meara A, Rovin BH. Update on lupus nephritis. CJASN. 2016;12:825–835.
   PubMed Web of Science ®Google Scholar
• Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46–53.
   PubMed Web of Science ®Google Scholar
• Parikh SV, Rovin BH. Current and emerging therapies for Lupus Nephritis. J Am Soc Nephrol. 2016;27:2929–2939.
   PubMed Web of Science ®Google Scholar
• Satoh M, Kumar A, Kanwar YS, et al. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA. 1995;92:10934–10938.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Szeto C, Han S, et al. Animal models of interferon signature positive lupus. Front Immunol. 2015;6:6–11.
   PubMed Web of Science ®Google Scholar
• dos Santos M, Poletti PT, Milhoransa P, et al. Unraveling the podocyte injury in lupus nephritis: clinical and experimental approaches. Semin Arthritis Rheum. 2017;46:632–641.
   PubMed Web of Science ®Google Scholar
• Stacchiotti A, Favero G, Giugno L, et al. Mitochondrial and metabolic dysfunction in renal convoluted tubules of obese mice: protective role of melatonin. PLoS One. 2014;9:e111141.
   PubMed Web of Science ®Google Scholar
• Stacchiotti A, Li Volti G, Lavazza A, et al. Different role of Schisandrin B on mercury-induced renal damage in vivo and in vitro. Toxicology. 2011;286:48–57.
   PubMed Web of Science ®Google Scholar
• D’Andrea G. Quercetin: a flavonol with multifaceted therapeutic applications?. Fitoterapia. 2015;106:256–271.
   PubMed Web of Science ®Google Scholar
• Alam MM, Meerza D, Naseem I. Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice. Life Sci. 2014;109:8–14.
   PubMed Web of Science ®Google Scholar
• Lai PB, Zhang L, Yang LY. Quercetin ameliorates diabetic nephropathy by reducing the expressions of transforming growth factor-β1 and connective tissue growth factor in streptozotocin-induced diabetic rats. Ren Fail. 2012;34:83–87.
   PubMed Web of Science ®Google Scholar
• Gomes IBS, Porto ML, Santos MCLFS, et al. Renoprotective, anti-oxidative and anti-apoptotic effects of oral low-dose quercetin in the C57BL/6J model of diabetic nephropathy. Lipids Health Dis. 2014;13:184.
   PubMed Web of Science ®Google Scholar
• Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. Br J Nutr. 2009;102:1065–1074.
   PubMed Web of Science ®Google Scholar
• Seo MJ, Lee YJ, Hwang JH, et al. The inhibitory effects of quercetin on obesity and obesity-induced inflammation by regulation of MAPK signaling. J Nutr Biochem. 2015;26:1308–1316.
   PubMed Web of Science ®Google Scholar
• Ishizawa K, Izawa-Ishizawa Y, Ohnishi S, et al. Quercetin glucuronide inhibits cell migration and proliferation by platelet-derived growth factor in vascular smooth muscle cells. J Pharmacol Sci. 2009;109:257–264.
   PubMed Web of Science ®Google Scholar
• Suwannaroj S, Lagoo A, Keisler D, et al. Antioxidants suppress mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus. 2001;10:253–257.
   PubMed Web of Science ®Google Scholar
• Li W, Li H, Zhang M, et al. Quercitrin ameliorates the development of systemic lupus erythematosus-like disease in a chronic graft-versus-host murine model. Am J Physiol Renal Physiol. 2016;311:F217–F226.
   PubMed Web of Science ®Google Scholar
• dos Santos M, Favero G, Bonomini F, et al. Oral supplementation of melatonin protects against lupus nephritis renal injury in a pristane-induced lupus mouse model. Life Sci. 2018;193:242–251.
   PubMed Web of Science ®Google Scholar
• Marcolin E, Forgiarini LF, Rodrigues G, et al. Quercetin decreases liver damage in mice with non-alcoholic steatohepatitis. Basic Clin Pharmacol Toxicol. 2013;112:385–391.
   PubMed Web of Science ®Google Scholar
• Favero G, Trapletti V, Bonomini F, et al. Oral supplementation of melatonin protects against fibromyalgia-related skeletal muscle alterations in reserpine-induced myalgia rats. IJMS. 2017;18:1389.
   Google Scholar
• Stacchiotti A, Favero G, Lavazza A, et al. Hepatic macrosteatosis is partially converted to microsteatosis by melatonin supplementation in ob/ob mice non-alcoholic fatty liver disease. PLoS One. 2016;11:e0148115.
   PubMed Web of Science ®Google Scholar
• Rezzani R, Favero G, Stacchiotti A, et al. Endothelial and vascular smooth muscle cell dysfunction mediated by cyclophylin A and the atheroprotective effects of melatonin. Life Sci. 2013;92:875–882.
   PubMed Web of Science ®Google Scholar
• Agabiti-Rosei C, Favero G, De Ciuceis C, et al. Effect of long-term treatment with melatonin on vascular markers of oxidative stress/inflammation and on the anticontractile activity of perivascular fat in aging mice. Hypertens Res. 2017;40:41–50.
   PubMed Web of Science ®Google Scholar
• Buege JA, Aust SD. Microsomal lipid peroxidation. Meth Enzymol. 1978;52:302–310.
   PubMedGoogle Scholar
• dos Santos M, Bringhenti RN, Rodrigues PG, et al. Podocyte-associated mRNA profiles in kidney tissue and in urine of patients with active lupus nephritis. Int J Clin Exp Pathol. 2015;8:4600–4613.
   PubMed Web of Science ®Google Scholar
• Panickar KS, Jewell DE. The beneficial role of anti-inflammatory dietary ingredients in attenuating markers of chronic low-grade inflammation in aging. Horm Mol Biol Clin Investig. 2015;23:59–70.
   PubMed Web of Science ®Google Scholar
• Reeves WH, Lee PY, Weinstein JS, et al. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009;30:455–464.
   PubMed Web of Science ®Google Scholar
• Freitas EC, de Oliveira MS, Monticielo OA. Pristane-induced lupus: considerations on this experimental model. Clin Rheumatol. 2017;36:2403–2414.
   PubMed Web of Science ®Google Scholar
• Lee KM, Hwang MK, Lee DE, et al. Protective effect of quercetin against arsenite-induced COX-2 expression by targeting PI3K in rat liver epithelial cells. J Agric Food Chem. 2010;58:5815–5820.
   PubMed Web of Science ®Google Scholar
• Angeloni C, Hrelia S. Quercetin reduces inflammatory responses in LPS-stimulated cardiomyoblasts. Oxid Med Cell Longev. 2012;2012:837104.
   PubMedGoogle Scholar
• Vollmer J, Tluk S, Schmitz C, et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves toll-like receptors 7 and 8. J Exp Med. 2005;202:1575–1585.
   PubMed Web of Science ®Google Scholar
• Zhou LLL, Wei W, Si JFF, et al. Regulatory effect of melatonin on cytokine disturbances in the pristane-induced lupus mice. Mediators Inflamm. 2010;2010:.
   Google Scholar
• Wang ZL, Luo XF, Li MT, et al. Resveratrol possesses protective effects in a pristane-induced lupus mouse model. PLoS One. 2014;9:e114792.
   PubMed Web of Science ®Google Scholar
• Yung S, Cheung KF, Zhang Q, et al. Mediators of inflammation and their effect on resident renal cells: implications in lupus nephritis. Clin Dev Immunol. 2013;2013:317682.
   PubMedGoogle Scholar
• Hsieh C, Chang A, Brandt D, et al. Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res. 2011;63:865–874.
   PubMed Web of Science ®Google Scholar
• Rhyu DY, Yang Y, Ha H, et al. Role of reactive oxygen species in TGF- 1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol. 2005;16:667–675.
   PubMed Web of Science ®Google Scholar
• Lu Q, Ji XJ, Zhou YX, et al. Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy. Pharmacol Res. 2015;99:237–247.
   PubMed Web of Science ®Google Scholar
• Kalaaji M, Mortensen E, Jørgensen L, et al. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol. 2006;168:1779–1792.
   PubMed Web of Science ®Google Scholar
• Badillo-Almaráz I, Daza L, Avalos-Díaz E, et al. Glomerular expression of Fas ligand and Bax mRNA in lupus nephritis. Autoimmunity. 2001;34:283–289.
   PubMed Web of Science ®Google Scholar
• Cui JH, Qiao Q, Guo Y, et al. Increased apoptosis and expression of FasL, Bax and caspase-3 in human lupus nephritis class II and IV. JN. 2012;25:255–261.
   Google Scholar
• Pereira Braga C, Momentti AC, Barbosa Peixoto F, et al. Influence of treatment with quercetin on lipid parameters and oxidative stress of pregnant diabetic rats. Can J Physiol Pharmacol. 2013;91:171–177.
   PubMed Web of Science ®Google Scholar
• Elbe H, Dogan Z, Taslidere E, et al. Beneficial effects of quercetin on renal injury and oxidative stress caused by ciprofloxacin in rats: a histological and biochemical study. Hum Exp Toxicol. 2016;35:276–281.
   PubMed Web of Science ®Google Scholar
• Fukuda A, Wickman LT, Venkatareddy MP, et al. Urine podocin:nephrin mRNA ratio (PNR) as a podocyte stress biomarker. Nephrol Dial Transpl. 2012;27:4079–4087.
   PubMed Web of Science ®Google Scholar
• Wickman L, Afshinnia F, Wang SQ, et al. Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases. J Am Soc Nephrol. 2013;24:2081–2095.
   PubMed Web of Science ®Google Scholar
• Perysinaki GS, Moysiadis DK, Bertsias G, et al. Podocyte main slit diaphragm proteins, nephrin and podocin, are affected at early stages of lupus nephritis and correlate with disease histology. Lupus. 2011;20:781–791.
   PubMed Web of Science ®Google Scholar
• Kraft SW, Schwartz MM, Korbet SM, et al. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16:175–179.
   PubMed Web of Science ®Google Scholar